NCT00472797

Rebif New Formulation (RNF) Quality of Life (QOL) Study

A Randomized, Multicenter, Two-arm, 12 Week Phase IIIb Study to Evaluate Quality of Life (QOL) Measures in Subjects With Relapsing Forms of Multiple Sclerosis (MS) Who Are Transitioning From Rebif® (Interferon Beta-1a) to Rebif New Formulation (RNF)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 232 (actual)
• Sponsor: EMD Serono · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).

Conditions

• Relapsing Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Rebif New Formulation Non Titrated	human interferon beta 1a - Rebif New Formulation
DRUG	Rebif New Formulation Titrated	Human interferon beta 1a Rebif New Formulation

Timeline

• Start date: 2007-04-01
• Primary completion: 2009-02-01
• Completion: 2009-11-01
• First posted: 2007-05-14
• Last updated: 2013-08-07
• Results posted: 2009-09-02

Locations

1 site across 1 country: United States